Artesunate/mefloquine in Brazil, India, and Malaysia. In 2012 a course of treatment cost 2.50 USD. It is not commercially available in the United States. Artesunate/mefloquine is a recommended treatment in Southeast Asia while in Africa artesunate/amodiaquine, artemether/lumefantrine, artesunate/sulfadoxine/pyrimethamine are often preferred. Artesunate/mefloquine Artesunate/mefloquine is a medication used to treat malaria. It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria. It is taken by mouth. Side effects are similar to the medications being used separately. Use is recommended as it decreases the possibility of either medications being used alone. Dose forms appropriate
Mefloquine clearance is through the liver, and the primary means of excretion is through the bile and feces, as opposed to only 4% to 9% excreted through the urine. During long-term use, the plasma half-life remains unchanged. Liver function tests should be performed during long-term administration of mefloquine. Alcohol use should be avoided during treatment with mefloquine. Mefloquine is a chiral molecule with two asymmetric carbon centres, which means it has four different stereoisomers. The drug is currently manufactured and sold as a racemate of the ("R","S")- and ("S","R")-enantiomers by Hoffman-LaRoche, a Swiss pharmaceutical company. Essentially, it is two drugs in